This review highlights the impact of senescence on mesenchymal stem cells, suggesting biomaterial strategies for rejuvenation and improved therapy outcomes in aging.
The capacity for tissue regeneration declines with age, and cellular senescence is recognized as a critical driver of aging and impaired tissue regeneration potential. Advances in stem cell research have provided new insights into tissue regeneration and stem cell therapy in aging-related diseases. However, stem cell senescence significantly limits their therapeutic efficacy, highlighting the need for effective rejuvenation strategies. Current antisenescence approaches have shown promise, but they still face limitations. This review summarizes and discusses the characteristics and consequences of mesenchymal stem cells (MSCs) senescence and evaluates existing antisenescence strategies. Additionally, recent advancements in biomaterials have demonstrated considerable potential in modulating stem cell fate and enhancing tissue regeneration outcomes. In this context, we explore biomaterial-based approaches for rejuvenating senescent MSCs, offering novel perspectives for advancing tissue regeneration therapies targeting aging-related diseases.
No takes yet. Share an insight, caveat, or question.
ZHANG et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: